Many neuropsychiatric disorders are treated using drugs that target the transmission of the neurotransmitter serotonin. However, the suboptimal efficacy of these drugs alongside new lines of research highlighting a role for serotonin in neurodevelopment have urged scientists to revisit the origins and treatment of these disorders. The EU-funded SEROTONIN and BEYOND project will work under the hypothesis that serotonin-related neuropsychiatric disorders are caused by neurodevelopmental changes. To address this scientific concept, the project will train early-stage researchers in state-of-the-art techniques, preparing them for a bright career in the field.
Our Early Stage Researchers will increase the level of critical knowledge in the multi-level trajectories through which serotonin shapes transdiagnostic behaviour and cognition during critical windows in brain development. Through the integration of neurotechnologies and preclinical-clinical research, new discoveries can be expected. Furthermore, the training we provide in S&B allows ESRs to deliver insights in critical windows for interventions as well as new ideas for future intervention approaches redirecting serotonin-mediated developmental changes. This will lead to improved prevention of these disorders and promote mental health.